We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
- Authors
Cady, Roger; Schreiber, Curtis
- Abstract
To examine the efficacy and safety of and satisfaction with botulinum toxin type A (BoNTA; BOTOX: Allergan, Inc., Irvine, CA) for prophylactic treatment of migraine headache in patients previously failing prophylaxis because of issues pertaining to compliance. Background.- Numerous factors (eg, adverse effects, tolerability, cost, frequency of dosage, hesitancy to take daily medication, failure to complete treatment) negatively influence compliance with the preventive pharmacology for migraine prophylaxis. BoNTA may offer benefit in improving compliance because of its long duration of action, injectable route of administration, and its tolerability (adverse event [AE]) profile.
- Publication
Headache, 2008, Vol 48, Issue 6, p900
- ISSN
1526-4610
- Publication type
Journal Article
- DOI
10.1111/j.1526-4610.2007.00953.x